Related Experiment Video
Updated: Jan 3, 2026
An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
Published on: July 20, 2014
Second-generation Src/Abl inhibitor bosutinib effectively induces apoptosis in human esophageal squamous cell
Y N E Ha1,2, Y Dai2, D Wufuer2
1Laboratory of Structural Biology, Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, China.
Abstract:
Esophageal cancer is a prevalent type of cancer worldwide and is ranked sixth among cancer-associated mortalities. Aberrant activation of the non-receptor tyrosine kinase Src and c-Abl contribute to the progression of ESCC. Thus, targeting these kinases to treat ESCC is a promising strategy. In this paper, we report that the potent dual Src/Abl inhibitor bosutinib exerts anti-tumor effects on ESCC. Bosutinib inhibits ESCC cell proliferation in a dose-dependent manner. Furthermore, bosutinib suppresses the colony formation ability of ESCC cells. Mechanistically, bosutinib effectively inhibits c-Abl and Src and its downstream signaling pathways, PI3K/AKT/mTOR and JAK/STAT3. In addition, bosutinib enhances the cytotoxic effects of doxorubicin on ESCC cells. In summary, our results reveal that Src and Abl are potential therapeutic targets in ESCC and that the novel Src/Abl inhibitor bosutinib alone or in combination with other chemotherapeutic agents may be a viable option for treating ESCC patients.
Insights
Bosutinib, a dual Src/Abl inhibitor, shows anti-tumor effects against esophageal cancer (ESCC). It inhibits cancer cell growth and enhances chemotherapy, suggesting it as a potential treatment for ESCC.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Esophageal cancer (ESCC) is a leading cause of cancer mortality worldwide.
- Aberrant activation of Src and c-Abl tyrosine kinases drives ESCC progression.
- Targeting these kinases presents a promising therapeutic strategy for ESCC.
Purpose of the Study:
- To investigate the anti-tumor effects of the dual Src/Abl inhibitor bosutinib on ESCC.
- To elucidate the molecular mechanisms underlying bosutinib's action in ESCC.
- To evaluate bosutinib's potential in combination therapy for ESCC.
Main Methods:
- In vitro studies assessing ESCC cell proliferation and colony formation.
- Western blot analysis to examine the inhibition of Src, c-Abl, and downstream pathways (PI3K/AKT/mTOR, JAK/STAT3).
- Assessment of bosutinib's effect on the cytotoxicity of doxorubicin in ESCC cells.
Main Results:
- Bosutinib demonstrated dose-dependent inhibition of ESCC cell proliferation and colony formation.
- Bosutinib effectively inhibited c-Abl, Src, and their downstream signaling pathways.
- Bosutinib enhanced the cytotoxic effects of doxorubicin on ESCC cells.
Conclusions:
- Src and Abl are validated as potential therapeutic targets in ESCC.
- Bosutinib exhibits significant anti-tumor activity against ESCC, both as a single agent and in combination therapy.
- Bosutinib represents a viable therapeutic option for treating patients with esophageal cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:31The Intrinsic Apoptotic Pathway
02:34Inhibition of Cdk Activity
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...